Exploring the Impact of CDK 4/6 Inhibitors Through Case-Based Panel Discussion

Speciality: Rheumatology


Speaker:

Dr. Narendra Agarwal | Sr. Consultant, Hematology, RGCIRC

Dr. Rayaz Ahmed | Sr. Consultant, Hematology, RGCIRC

Dr. Narender Tejwani | Consultant Hematopathology, RGCIRC

Description:

A warm welcome to all the medical professionals in this case-based panel discussion on the role of CDK 4/6 inhibitors in clinical practice. 

Cyclin-dependent kinase (CDK) 4/6 inhibitors are a class of anticancer medications. It is also helpful in reducing or eliminating endocrine resistance when used in combination with endocrine therapy. It can be used for the treatment of hormone receptor–positive (HR+) breast cancer.

The CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib are observed to enhance the change in the treatment paradigm for patients with HR+/HER2− advanced breast cancer. Moreover, these drugs have demonstrated a meaningful improvement in PFS when used for first- or later-line therapy.

Therefore, listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such interesting webinar sessions.
 


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.

2.

Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment

3.

Racial differences seen in epigenetic age acceleration in childhood cancer survivors

4.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

5.

Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot